Klervi Desrumeaux

Klervi DESRUMEAUX has over a decade of experience in antibody discovery and engineering, currently serving as Group Head at Sanofi since January 2016, focusing on immuno-oncology projects involving phage display and biochemical characterization of antibodies. Prior to this, Klervi held the position of Scientific Project Manager at THERAVECTYS, directing in vitro selection and characterization of nanobodies for immunology and oncology, and contributing to the development of anti-checkpoint nanobodies and CAR T cell therapy strategies. Klervi's career began with a postdoctoral role at Institut Curie, specializing in the selection and characterization of tumor-specific nanobodies, alongside doctoral research at INSERM that involved discovering new targets for breast cancer diagnosis and therapy using phage display and nanobody technology. Klervi obtained a Master's degree in Immunotechnologies from Université Aix Marseille II Luminy and a DEUG in Life Sciences from Université Côte d'Azur.